eGFR did not significantly change with supplementation versus placebo in patients with type 2 diabetes
FRIDAY, Nov. 8, 2019 (HealthDay News) — Supplementation with vitamin D3 or omega-3 fatty acids does not result in a significant difference in change in estimated glomerular filtration rate (eGFR) at five years versus placebo among adults with type 2 diabetes, according to a study published online Nov. 8 in the Journal of the American Medical Association. The research was published to coincide with Kidney Week, the annual meeting of the American Society of Nephrology, held from Nov. 5 to 10 in Washington, D.C.
Ian H. de Boer, M.D., from the University of Washington in Seattle, and colleagues conducted a randomized trial among 1,312 adults with type 2 diabetes. Participants were randomly assigned to receive vitamin D3 and omega-3 fatty acids, vitamin D3 and placebo, placebo and omega-3 fatty acids, or two placebos (370, 333, 289, and 320 participants, respectively) for five years; 71 percent completed the study.
The researchers found that from baseline to year 5, the mean change in eGFR was −12.3 versus −13.1 mL/min/1.73 m² with vitamin D3 versus placebo (difference, 0.9; 95 percent confidence interval, −0.7 to 2.5). The mean change in eGFR was −12.2 versus −13.1 mL/min/1.73 m² with omega-3 fatty acids versus placebo (difference, 0.9; 95 percent confidence interval, −0.7 to 2.6). No significant interaction was seen between the two interventions.
“These results suggest that neither vitamin D nor omega-3 fatty acids have appreciable kidney benefits among the broad population of patients with diagnosed type 2 diabetes,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry; one author disclosed holding a patent pending on a measurement of bioavailable vitamin D.
Copyright © 2019 HealthDay. All rights reserved.